| pubmed-article:21222363 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21222363 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:21222363 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:21222363 | lifeskim:mentions | umls-concept:C0449438 | lld:lifeskim |
| pubmed-article:21222363 | lifeskim:mentions | umls-concept:C1414313 | lld:lifeskim |
| pubmed-article:21222363 | lifeskim:mentions | umls-concept:C1707391 | lld:lifeskim |
| pubmed-article:21222363 | lifeskim:mentions | umls-concept:C0033522 | lld:lifeskim |
| pubmed-article:21222363 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21222363 | pubmed:dateCreated | 2011-1-12 | lld:pubmed |
| pubmed-article:21222363 | pubmed:abstractText | We prospectively investigated the outcome of personalized second-line treatment based on epidermal growth factor receptor (EGFR) gene status in previously treated patients with advanced non-small cell lung cancer (NSCLC). EGFR gene status was evaluable by LH-mobility shift assay in registered patients. Gefitinib (Gef) treatment was recommended if the patients had EGFR mutation (mEGFR). EGFR gene status was evaluable in 146 patients. Seventy-four of the patients were female, 82 were smokers, and 122 had adenocarcinoma. Overall, 67 patients had mEGFR and received Gef. Forty-nine of 79 patients with wild-type EGFR (wEGFR) received other chemotherapies or radiation but 30 selected best supportive care only as a second-line treatment. Patients with mEGFR survived significantly longer than patients with wEGFR (p < 0.0001). However, the survival of patients who received other forms of chemotherapy was not different from that of patients who received best supportive care only as a second-line treatment in patients with wEGFR. Examination of the association between overall survival after first-line chemotherapy and prognostic factors using multivariate regression analysis showed that mEGFR and response to first-line chemotherapy were independent factors (p = 0.003 and p = 0.003, respectively). Selection of second-line treatment according to EGFR gene status may be useful for patients with NSCLC. | lld:pubmed |
| pubmed-article:21222363 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21222363 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21222363 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21222363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21222363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21222363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21222363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21222363 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21222363 | pubmed:issn | 1359-4117 | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:OshitaFumihir... | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:KamedaYoichiY | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:SaitoHaruhiro... | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:YamadaKouzoK | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:NodaKazumasaK | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:HondaTakeshiT | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:MiyagiYoheiY | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:YokoseTomoyuk... | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:KondoTetsuroT | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:SakumaYujiY | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:MurakamiShuji... | lld:pubmed |
| pubmed-article:21222363 | pubmed:author | pubmed-author:ObataMasatoM | lld:pubmed |
| pubmed-article:21222363 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:21222363 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:21222363 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21222363 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21222363 | pubmed:pagination | 313-9 | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:meshHeading | pubmed-meshheading:21222363... | lld:pubmed |
| pubmed-article:21222363 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:21222363 | pubmed:articleTitle | Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status. | lld:pubmed |
| pubmed-article:21222363 | pubmed:affiliation | Department of Thoracic Oncology, Kanagawa Cancer Center Nakao 1-1-2, Asahi-ku, Yokohama 241-0815, Japan. foshita@kcch.jp | lld:pubmed |
| pubmed-article:21222363 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21222363 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
